Resmonics
Enabling respiratory symptom monitoring in your app.
Tell Me More Book A Demo

Resmonics presents:

RESGUARD MED

It's hard to get people excited about health apps. Most patients and physicians think of them as gimmicks,
which are at best nice-to-have tools.

With ResGuard Med, your health app becomes a must-have for patients overnight.
Our AI-based technology enables your app to offer objective, clinically validated, and CE-certified nocturnal respiratory symptom tracking and assessment.

Book a demo to find out how ResGuard Med can help you to get patients with respiratory diseases and their physicians excited about your app. It is time that your app becomes an integral part of your users’ everyday lives.

Integrate ResGuard Med into your app

Our technology can be used for chronic disease management, triage, or hospital-at-home use cases in adults.

Nocturnal respiratory symptom monitoring for your users

We’ve spent many years on research, R&D, and clinical validation so that you don’t need to.

Unique disease insights and early respiratory crisis warnings

Your app now generates unique and objective insights that patients cannot obtain anywhere else.

Additional benefits of our medical software

You stay in full control of any generated data. Our CE certification protects users and allows you to make medical claims.

Technology

Strong claims require strong evidence. Our products are based on five years of deep learning and respiratory medicine research. Explore our growing evidence base by browsing through an excerpt of our peer-reviewed papers and posters.

"There was no method available for doctors to measure cough. But this would be important to objectify the success of medication and interventions: Cough can be used as a biomarker for the disease activity of asthma, COPD, interstitial and fibrotic lung diseases, upper and lower respiratory tract infections. Resmonics now fills exactly this gap - objective cough measurement via smartphone!"

Prof. Martin Brutsche

Chief Physician at the Clinic for Pneumology and Sleep Medicine & Director of the Lung Center at the Cantonal Hospital St. Gallen

"Resmonics' technology for the objective tracking of lung symptoms closes an important treatment gap in the everyday life of my patients. Noteworthy: The Technology works completely anonymously: user data is not required (no user account needs to be created) and no identifiable data (GPS etc.) is uploaded."

Dr. Patrick Stais

Managing Senior Physician of the Clinic for Pulmonary & Bronchial Medicine at the Hospital Bethanien Moers

Preliminary results of cough monitoring for Covid-19 patients

ERS International Congress

Towards cough as a digital biomarker for COPD patients

Careum Weiterbildung

24/7 Cough monitoring in hospitalized patients

Swiss MedTech Day 2020

Nocturnal cough and sleep quality as markers for asthma

Journal of Asthma & Allergy

Deep learning cough detection in real-world asthma

JMIR 2020

Characteristics of nocturnal cough in asthma

Journal of Asthma & Allergy

Deep learning breathing pattern detection

UbiComp 2019

Device-agnostic cough detection with deep learning

IEEE ICHI 2019

Nocturnal cough and sleep quality as markers for asthma

BMJ Open

Systematic review of publicly available asthma apps

JMIR mhealth and uhealth

Enhancing asthma control through IT (mHealth)

WI Conference

Featured News

  1. Resmonics wins
    Venture Kick II
  2. Financing round
    closed
  3. Selected for the Swiss
    Startup National Team
  4. Resmonics wins
    Venture Kick III
  5. Award Winner
    @Digital Health Lab Day
  6. Resmonics launches
    in Finland and Switzerland

  1. CHF 40,000 for startups developing oral microbiome therapies to treat chronic kidney disease and solutions to monitor asthma

    November 24th, 2020

    Resmonics win Venture Kick's second stage of financial and entrepreneurial support. Their project helps patients monitor their asthma at night and prevent attacks. Read More

  2. Respiratory Health Tech Startup Resmonics Closes its Pre-Seed Financing Round

    January 10th, 2021

    Zurich, Switzerland, January 19th, 2021 – Recently incorporated digital biomarker startup Resmonics has received financial support from the CSS insurance in its pre-seed financing round. The due diligence was conducted by Redstone on behalf of CSS Insurance. The funding will be used to accelerate the development of its first product, a smartphone-based digital biomarker service for patients suffering from asthma or COPD, and to certify it as a medical device. ... Read More

  3. Resmonics got selected for the Venture Leaders Mobile National Team

    April 16th, 2021

    The jury of Venture Leaders Mobile 2021 selected 10 start-ups. They represent a range of sectors from digital health to insurtech and advance innovations in artificial intelligence, big data, or blockchain. The selected teams will travel to Barcelona to attend the Mobile World Congress from June 28–July 1, 2021, planned as an in-person event with hybrid experiences. Read More

  4. Resmonics wins CHF 150,000 to turn the smartphones of patients with chronic respiratory diseases into guardian angels

    June 23rd, 2021

    Resmonics wins Venture Kick's final stage of financial and entrepreneurial support. Their first product, ResGuard Med, is a CE-certified early-warning system that helps patients with chronic respiratory diseases manage their condition. Read More

  5. Expert jury selects Resmonics as the best digital health startup at the 3rd digital health lab day by ZHAW

    September 16th, 2021

    We congratulate the Digital Health Lab Day 2021 Startup pitching winner in the category "Jury Voting": Resmonics. The startup prevailed over the 8 other finalists on the basis of 5 evaluation dimensions. Read More

  6. Resmonics launches in Finland and Switzerland

    January 20th, 2022

    In collaboration with Finish KAMU Health and Swiss CSS insurance, ETH spinoff Resmonics has launched its first product ResGuard Med. The CE-certified solution gives patients with chronic and acute respiratory symptoms unique insights into their disease. Read More

Meet the team

Our core value is to develop innovative technology to improve patients' everyday lives. We operate at the intersection of respiratory medicine, artificial intelligence, and business innovation.

“My MSc in psychology and years of research experience in digital health made me realize that it is often more worthwhile to change technology than human behavior, in particular in chronic care.”

Dr. Peter Tinschert

Co-Founder, CEO

“My PhD and my computer science degree taught me how to build state-of-the-art tech. What excites me the most, however, is when technology actually improves patient lives in the real world.”

Dr. Iris Shih

Co-Founder, CTO

Ihor Khomich

Senior Full Stack Developer

David Cleres

Senior Data Scientist

Katharina Smiatek

Data Scientist

Davor Perhaj

Freelance UX/UI Consultant

Interested to learn more?
Book a demo or get in touch with us here.

We would love to get in contact with you!